Mrinal M. Gounder, MD, discusses the rationale for investigating nirogacestat in the DeFi trial, highlights patient-reported outcomes with the agent in this study, and discusses potential next steps for better utilizing T2-weighted magnetic resonance imaging in addition to RECIST criteria when assessing tumor volume and dimensions in desmoid tumors.
Meredith McKean, MD, MPH, discusses the efficacy and safety of treatment with the anti-TGIT agent etigilimab and the PD-1 inhibitor nivolumab in patients with solid tumors and PD-L1-low disease.
Breelyn A. Wilky, MD, discusses the rationale for investigating the combination of zalifrelimab, balstilimab, and doxorubicin in patients with advanced/metastatic soft tissue sarcoma, and early results from a phase 2 trial.
The oral MDM2/p53 antagonist BI 907828 elicited preliminary antitumor activity and had a manageable safety profile in patients with MDM2-amplified dedifferentiated liposarcoma.